JP2018528276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528276A5 JP2018528276A5 JP2018534524A JP2018534524A JP2018528276A5 JP 2018528276 A5 JP2018528276 A5 JP 2018528276A5 JP 2018534524 A JP2018534524 A JP 2018534524A JP 2018534524 A JP2018534524 A JP 2018534524A JP 2018528276 A5 JP2018528276 A5 JP 2018528276A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor cell
- cell preparation
- inactivated
- ptcp
- inactivated tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cells Anatomy 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 2
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- 206010028549 Myeloid leukaemia Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
Claims (4)
- 生体内で患者のＮＫ細胞をプライミングするための不活性化腫瘍細胞調製物（ＰＴＣＰ）を患者に導入することを含む癌の治療用の不活性化腫瘍細胞調製物であって、
ＣＴＶ−１骨髄性白血病細胞株由来の細胞または膜部分を含む、不活性化腫瘍細胞調製物。 - 前記ＰＴＣＰが、不活性化を達成するために放射線照射されてなる請求項１に記載の不活性化腫瘍細胞調製物。
- 前記不活性化されたＰＴＣＰが、放射線照射された細胞またはその膜部分を含む請求項１に記載の不活性化腫瘍細胞調製物。
- 前記ＰＴＣＰが、非晶質炭水化物−ガラスマトリックスに固定され、放射線照射されることにより不活性化されてなる請求項３に記載の不活性化腫瘍細胞調製物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263951P | 2015-12-07 | 2015-12-07 | |
| US62/263,951 | 2015-12-07 | ||
| PCT/US2016/061835 WO2017049327A2 (en) | 2015-09-16 | 2016-11-14 | In vivo priming of natural killer cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528276A JP2018528276A (ja) | 2018-09-27 |
| JP2018528276A5 true JP2018528276A5 (ja) | 2019-12-12 |
| JP6850297B2 JP6850297B2 (ja) | 2021-03-31 |
Family
ID=63681977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534524A Active JP6850297B2 (ja) | 2015-12-07 | 2016-11-14 | ナチュラルキラー細胞の生体内プライミング |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6850297B2 (ja) |
| DK (1) | DK3349769T3 (ja) |
| ES (1) | ES2871100T3 (ja) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006224313B2 (en) * | 2005-03-17 | 2011-08-11 | Ucl Biomedica Plc | Method for actvating Natural Killer cells by tumor cell preparation in vitro |
| WO2011004201A1 (en) * | 2009-07-10 | 2011-01-13 | Mark Lowdell | Preserved compositions of activated nk cells and methods of using the same |
| WO2013132256A1 (en) * | 2012-03-07 | 2013-09-12 | Ucl Business Plc | Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals |
-
2016
- 2016-11-14 JP JP2018534524A patent/JP6850297B2/ja active Active
- 2016-11-14 DK DK16847576.2T patent/DK3349769T3/da active
- 2016-11-14 ES ES16847576T patent/ES2871100T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018081476A3 (en) | Viral methods of t cell therapy | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| WO2016100261A3 (en) | Method of treating cancer with cgamp or cgasmp | |
| WO2015195889A3 (en) | Induced photodynamic therapy using nanoparticle scintillators as transducers | |
| GB2521562A (en) | Anti-tumor T cell immunity induced by high dose radiation | |
| WO2018102452A3 (en) | Using substituted pyrazole compounds for treatment of hyperproliferative diseases | |
| JP2016501013A5 (ja) | ||
| WO2016201450A3 (en) | Cancer treatment and diagnosis | |
| JP2008536487A5 (ja) | ||
| PH12017501993A1 (en) | Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy | |
| MX2018000052A (es) | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. | |
| WO2019028406A3 (en) | Activation of resident memory t cells for the treatment of cancer | |
| CR11631A (es) | Paramyxovirus eficaz como antitumoral | |
| MX2021005421A (es) | Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos. | |
| JP2013536236A5 (ja) | ||
| BR112023018237A2 (pt) | Fenalquilaminas e métodos para fabricação e uso das mesmas | |
| WO2015112850A3 (en) | Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders | |
| WO2019210888A3 (zh) | 抗结核病疫苗及其制备方法和用途 | |
| DE602008003199D1 (de) | Glucoseisomerase zur behandlung von fructose-unverträglichkeit | |
| Vendrely et al. | Local excision versus total mesorectal excision in patients with good response after neoadjuvant radiochemotherapy for T2-T3 low rectal cancer: preliminary results of the GRECCAR 2 randomized phase 3 trial | |
| JP2018528276A5 (ja) | ||
| WO2011028485A3 (en) | Tumoricidal, bactericidal, or viricidal macrophage activation | |
| WO2015040497A3 (en) | Methods for nuclear reprogramming of cells | |
| WO2017049327A3 (en) | In vivo priming of natural killer cells | |
| SG11202103342QA (en) | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |